AssetMark Inc’s Travere Therapeutics TVTX Stock Holding History

AssetMark Inc’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.12M	Sell	19,063 -717	-4%	-$43.8K	﹤0.01%	1069
2026 Q2	$1.12M	Buy	19,780 +144	+0.7%	+$6.38K	﹤0.01%	1068
2026 Q1	$583K	Sell	19,636 -1,931	-9%	-$57.7K	﹤0.01%	1136
2025 Q4	$824K	Buy	+21,567	New	+$701K	﹤0.01%	1058

Other funds holding TVTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

AssetMark Inc's TVTX Position: Q3 2026 in Review

AssetMark Inc reduced its Travere Therapeutics (TVTX) stake by 3.6% in Q3 2026, selling an estimated $43.8K and leaving 19,063 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1069.

AssetMark Inc first reported a position in TVTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.12M in Q2 2026. 95 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

AssetMark Inc held 19,063 shares of Travere Therapeutics worth $1.12M as of Q3 2026.
AssetMark Inc sold 717 Travere Therapeutics shares in Q3 2026, an estimated $43.8K.
Travere Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1069 holding.
AssetMark Inc first reported a position in Travere Therapeutics in Q4 2025 and has held it in 4 quarters since.
AssetMark Inc's Travere Therapeutics position peaked at $1.12M in Q2 2026.
95 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.